Is AOD-9604 Legal in Tennessee? What Women Need to Know Before Ordering

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically amino acids 176 to 191. Researchers isolated this segment because animal studies suggested it could stimulate fat breakdown and inhibit new fat formation without the blood-sugar effects associated with full hGH. The "AOD" abbreviation stands for Anti-Obesity Drug, a name assigned during its original clinical development by the Australian company Metabolic Pharmaceuticals in the early 2000s.

The peptide does not bind the main hGH receptor. Instead, it appears to act on beta-adrenergic receptors in fat tissue, a mechanism that makes it conceptually distinct from growth hormone itself and from GLP-1 receptor agonists like semaglutide. That mechanistic difference matters for how regulators categorize it and, for women specifically, how it may interact with hormonal physiology across the menstrual cycle and at menopause.

Why Women Are Looking at AOD-9604

Interest among women has grown sharply alongside the GLP-1 medication shortage and rising out-of-pocket costs for semaglutide and tirzepatide. Women searching for alternatives, particularly those managing PCOS-related visceral adiposity, perimenopausal weight redistribution, or post-bariatric weight regain, are increasingly encountering AOD-9604 on wellness platforms, med spas, and telehealth sites.

The honest picture is that the human clinical data is thin. Metabolic Pharmaceuticals completed Phase 2 trials in the early 2000s showing modest weight loss of approximately 3 kg over 12 weeks in obese adults, with no serious adverse events reported in those trials. Those Phase 2 results were published in the International Journal of Obesity in 2004. Phase 3 was never completed, the program was discontinued, and AOD-9604 never received approval from the FDA, the TGA in Australia, or any other major regulatory agency. Women were included in those trials, but no sex-stratified efficacy or safety data was published separately. That evidence gap is real and worth stating plainly.

The Federal Legal Framework: Where AOD-9604 Actually Stands

The federal picture is the most important place to start, because Tennessee pharmacy law does not operate independently of FDA authority over compounded drugs.

FDA's 503A and 503B Bulk Compounding Lists

Under the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare drugs from bulk active pharmaceutical ingredients (APIs) only if those ingredients appear on specific FDA-approved lists. Section 503A governs traditional compounding pharmacies that prepare drugs for individual patients based on a valid prescription. Section 503B governs outsourcing facilities that compound in larger batches.

AOD-9604 was nominated for inclusion on the 503A bulk list. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed it, and the FDA did not add it to the positive list of bulk substances that may be used in compounding. A substance that is not on that list cannot lawfully be compounded by a 503A pharmacy and dispensed to a patient under a prescription in the United States. The same logic applies under 503B.

This is the central federal constraint. No Tennessee physician prescribing AOD-9604 and no Tennessee compounding pharmacy filling that prescription can do so in compliance with current federal law, regardless of how the prescription is written or what clinical rationale is provided.

The "Research Chemical" Distinction

Some vendors sell AOD-9604 labeled "for research use only" and "not for human consumption." Purchasing a substance under that label does not make its administration to patients legal. If a licensed clinician orders or administers it to you in that form, they are operating outside the boundaries of the federal drug compounding framework and potentially outside their state medical practice act. That is a meaningful risk for both you and the provider.

Tennessee-Specific Legal Framework

Tennessee does not have a separate statute that explicitly lists AOD-9604 by name as a banned or approved substance. The Tennessee Board of Pharmacy and the Tennessee Department of Health regulate compounding pharmacies and medical practice within the state, but they operate within and generally defer to the federal framework established by the FDA.

Tennessee Board of Pharmacy

The Tennessee Board of Pharmacy licenses compounding pharmacies operating in the state and requires them to follow USP standards and federal compounding law. A Tennessee-licensed compounding pharmacy that prepares AOD-9604 for patient use would be compounding a substance not on the FDA bulk list, which puts its federal compliance and state licensure at risk. No specific Tennessee advisory or enforcement action targeting AOD-9604 was publicly available as of this article's review date, but the absence of a state-specific ban does not create permission to compound or prescribe a federally restricted substance.

Tennessee Medical Practice Act

Under Tennessee Code Annotated Title 63, Chapter 6, physicians and advanced practice registered nurses (APRNs) have authority to prescribe drugs for legitimate medical purposes within the standard of care. Prescribing a peptide that cannot be lawfully compounded, sourced from an unregulated vendor, and administered outside established clinical evidence does not comfortably fit within that standard. The Tennessee Medical Board has disciplined providers for off-label prescribing practices that fall outside the standard of care, though no AOD-9604-specific case has been publicly documented.

What This Means Practically for You in Tennessee

If you are a woman in Tennessee who has been quoted AOD-9604 by a med spa, wellness clinic, or online telehealth platform, ask directly:

• Where is the peptide sourced?
• Is the compounding pharmacy on the FDA's list of registered outsourcing facilities?
• How does your practice comply with 503A/503B bulk substance requirements?

If those questions receive vague answers, that is meaningful clinical and legal information.

How This Compares to Legal Peptides Available in Tennessee

Not all peptides are in the same regulatory situation. For context:

Semaglutide was compounded legally during the FDA shortage period because it appeared on shortage lists that permitted compounding. That window has closed for brand-name semaglutide as the FDA has removed it from shortage status. The FDA's current position is that compounded semaglutide by 503A and 503B pharmacies is no longer permitted in most circumstances.

Sermorelin, a growth hormone releasing hormone (GHRH) analog, has a different compounding history and appears in more regulated compounding contexts, though its own legal status requires case-by-case assessment. Bremelanotide (PT-141) received FDA approval for HSDD in premenopausal women under the brand name Vyleesi in 2019, giving it a distinct legal pathway.

AOD-9604 has none of these pathways. It was never approved. It is not on a shortage list. It is not on the positive bulk compounding list. Its legal access route in the U.S. Is, at present, effectively closed for clinical use.

Sex-Specific Physiology: How Hormonal Status May Interact With AOD-9604

This section covers what is known and, equally, what is not known about AOD-9604 in women specifically.

Menstrual Cycle and Fat Metabolism

Women's fat metabolism changes across the menstrual cycle. Estrogen promotes subcutaneous fat storage and modestly protects against visceral fat accumulation during the reproductive years. After menopause, estrogen decline shifts fat distribution centrally, increasing cardiovascular and metabolic risk. Any agent targeting fat mobilization through beta-adrenergic pathways may theoretically interact with this hormonal context. No published data from the AOD-9604 trials has examined outcomes by menstrual cycle phase, ovarian reserve, or estrogen status. That gap is not a minor detail. It means clinicians cannot tell you with evidence whether AOD-9604 works differently, or is more or less safe, depending on where you are in your cycle or whether you are perimenopausal.

PCOS and Insulin Sensitivity

PCOS affects approximately 8 to 13 percent of women of reproductive age and is strongly associated with visceral adiposity, insulin resistance, and dyslipidemia. Women with PCOS frequently investigate off-label and emerging metabolic agents because first-line lifestyle interventions often produce limited visceral fat reduction. AOD-9604's proposed mechanism, preferential lipolysis without insulin-axis effects, is conceptually interesting in this population. The 2004 Phase 2 trial found no significant change in fasting insulin or glucose at doses up to 1 mg/day for 12 weeks. That is a single result in a non-PCOS-specific cohort and cannot be generalized as a safety endorsement for women with insulin resistance. Evidence is extrapolated, not directly studied.

Perimenopausal Fat Redistribution

Perimenopause, the transition that typically begins in the mid-40s and lasts four to ten years, is marked by fluctuating and ultimately declining estrogen and progesterone. Visceral fat accumulates at a rate roughly double that seen in the reproductive years during this period. Women in perimenopause who are frustrated with GLP-1 access or cost are among the most common inquirers about AOD-9604. The trial data does not include a perimenopausal or postmenopausal cohort with reported estrogen levels, so the claim that AOD-9604 is effective or safe in this life stage is entirely extrapolated.

Pregnancy, Lactation, and Contraception: What You Must Know

AOD-9604 should not be used during pregnancy or while breastfeeding.

There are no human pregnancy safety data for AOD-9604. There are no published teratogenicity studies in animal models that have been peer-reviewed. The compound has no FDA pregnancy category assigned because it was never approved. The FDA's current framework for unapproved substances places the full burden of risk assessment on the prescriber, and in the absence of data, the only defensible clinical position is to avoid use entirely during pregnancy and lactation.

Lactation Transfer

No pharmacokinetic data on lactation transfer exists for AOD-9604. Peptides administered subcutaneously are partially degraded in the bloodstream and gut, but breast milk transfer of peptide fragments is not zero, and the effect on an infant's developing endocrine system is unknown. Lactating women should not use AOD-9604.

Contraception Requirements

AOD-9604 is not a known teratogen in the way that isotretinoin or thalidomide are, but the absence of teratogenicity data is not evidence of safety. Women of reproductive age who choose to use AOD-9604 through any available route should use effective contraception and discuss pregnancy planning with their provider before starting. If you are actively trying to conceive, AOD-9604 use is not appropriate given the complete absence of data in this context.

Fertility Considerations

No data shows AOD-9604 impairs fertility. No data shows it is safe for use during a conception attempt either. Women undergoing fertility treatment or planning IVF should disclose any peptide use to their reproductive endocrinologist, as the interactions with ovarian stimulation protocols and gonadotropin signaling are entirely unstudied.

A Practical Framework for Women in Tennessee Considering AOD-9604

Given the legal and clinical picture, here is a structured way to think through your options if you are a woman in Tennessee who has been considering AOD-9604 for weight management or metabolic health.

Step 1: Clarify your underlying goal.

Is your goal visceral fat reduction? Metabolic health improvement in the setting of PCOS or perimenopausal weight gain? Or general weight loss? Each of these goals has evidence-based pathways that do not require legally ambiguous compounds.

Step 2: Ask whether a FDA-approved option addresses your need.

For weight management, FDA-approved options include orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide (Wegovy), and tirzepatide (Zepbound). For PCOS-related insulin resistance, metformin has decades of data in women, including in pregnancy. For perimenopausal visceral fat, menopausal hormone therapy has evidence for reducing central adiposity and improving metabolic markers in the perimenopause-to-early-postmenopause window.

Step 3: If you are offered AOD-9604 by a Tennessee provider, ask these specific questions.

Ask where the compound is sourced. Ask whether the pharmacy is a 503A or 503B registered facility. Ask how the provider documents clinical justification. Ask what monitoring is included. A provider who cannot answer these questions with specificity is not in a position to manage your safety.

Step 4: Weigh real versus hypothetical benefit.

The largest human trial of AOD-9604 showed approximately 3 kg of weight loss over 12 weeks. That is a modest effect, seen in a small, non-sex-stratified cohort, from a compound that currently has no legal compounding pathway in the U.S. The benefit calculation changes meaningfully when legal access is uncertain and monitoring is absent.

Who This Is and Is Not Right For

Women for Whom Legal, Monitored Alternatives Are the Better Choice

• Women who are pregnant, breastfeeding, or trying to conceive. No exceptions.
• Women with a BMI <27 and no metabolic comorbidities, where the risk-benefit ratio for any off-label metabolic agent is unfavorable.
• Women with active thyroid disease who have not yet optimized thyroid treatment. Uncontrolled thyroid function significantly affects fat metabolism and would confound any peptide effect.
• Women with a history of growth hormone-sensitive conditions, including certain cancers, as the hGH-fragment origin of AOD-9604 raises theoretical concerns not yet studied.

Women Who May Be Asking the Right Question but Need a Better Answer

• Perimenopausal women with new central adiposity who have not yet been evaluated for menopausal hormone therapy.
• Women with PCOS who have not yet tried GLP-1 receptor agonists or metformin with adequate titration.
• Postpartum women experiencing metabolic changes. AOD-9604 is not appropriate during lactation; a supervised return to physical activity and caloric adjustment with dietitian support is the evidence-based starting point.

The Evidence Gap in Women: A Note on Trial Representation

The 2004 Metabolic Pharmaceuticals trial, the most-cited human study on AOD-9604, enrolled obese adults but did not publish sex-stratified outcomes. Women have historically been underrepresented in metabolic and obesity trials, a problem documented extensively in the literature. A 2021 analysis in JAMA Network Open found that women remain underrepresented in cardiovascular and metabolic clinical trials relative to disease burden. For AOD-9604 specifically, no published trial reports outcomes by sex, hormonal status, menstrual cycle phase, or menopausal stage. Every claim about AOD-9604's effects in women is therefore extrapolated from a mixed-sex adult sample that was never adequately characterized by sex. That is not a reason to assume it does not work in women. It is a reason to be clear-eyed that no one knows.